

# Blastomycosis

Jennifer Tat MD MSc, Jeya Nadarajah MD MSc, Julianne V. Kus MSc PhD

■ Cite as: *CMAJ* 2023 July 31;195:E984. doi: 10.1503/cmaj.230269

## 1 *Blastomyces dermatitidis* and *Blastomyces gilchristii* are dimorphic fungal pathogens that have expanded their environmental range beyond the Great Lakes region and the St. Lawrence, Mississippi and Ohio River valleys

Although rates of blastomycosis in Canada remain low outside of historically endemic areas, the range for *Blastomyces* now includes Quebec, Manitoba, Saskatchewan, Ontario — the Kenora area has the highest global rates — and the eastern United States.<sup>1–3</sup> Changes in climate and land use are hypothesized to be causing the expansion.<sup>2</sup> Although a travel and exposure history remains important to differential diagnosis, cases are increasingly described in patients who have not travelled to traditional endemic areas.

## 2 *Blastomyces* can infect immunocompetent and immunocompromised people<sup>4</sup>

*Blastomyces* grows in soil and decaying vegetative material. Blastomycosis is typically acquired through inhalation of spores from the disrupted environment and, occasionally, through cutaneous inoculation; it does not spread person-to-person.<sup>4</sup> Indigenous people have a higher incidence of disease.<sup>3</sup> Other mammals, including domestic dogs, are susceptible.

## 3 Blastomycosis primarily manifests as a pulmonary infection, with presentations ranging from asymptomatic to mild, nonresolving pneumonia to acute respiratory distress syndrome

The incubation period is 4–6 weeks. Disease disseminates beyond the lungs in 20%–50% of cases, mainly to skin and bone.<sup>3,4</sup> Blastomycosis can mimic community-acquired pneumonia, tuberculosis or cancer.<sup>4</sup> Diagnosis is often delayed given the varied presentations and failure to consider blastomycosis.<sup>4</sup>

## 4 Microbiologic culture is the gold standard for diagnosis but can take days to weeks

Rapid presumptive diagnosis, sufficient for treatment decisions, can be made based on microscopic visualization of the characteristic yeast on specimens, especially from sputum or biopsy.<sup>4,5</sup> Antigen detection assays have high sensitivity but can cross-react with other fungi.<sup>5</sup> Serology is generally less sensitive and radiological manifestations can vary.

## 5 Treatment is determined by severity, immune status and clinical response, and involves prolonged, systemic antifungal therapy

Oral itraconazole is the drug of choice for mild-to-moderate disease; severe disease requires initial therapy with liposomal amphotericin B, followed by step-down therapy with an azole compound.<sup>4</sup>

## References

1. Surveillance of blastomycosis. Ottawa: Public Health Agency of Canada; 2016 Available: <https://www.canada.ca/en/public-health/services/diseases/blastomycosis/surveillance-blastomycosis.html> (accessed 2023 Apr. 5).
2. Ashraf N, Kubat RC, Poplin V, et al. Re-drawing the maps for endemic mycoses. *Mycopathologia* 2020;185:843-65.
3. Dwight PJ, Naus M, Sarsfield P, et al. An outbreak of human blastomycosis: the epidemiology of blastomycosis in the Kenora catchment region of Ontario, Canada. *Can Commun Dis Rep* 2000;26:82-91.
4. Chapman SW, Dismukes WE, Proia LA, et al. Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. *Clin Infect Dis* 2008;46:1801-12.
5. Hage CA, Carmona EM, Epelbaum O, et al. Microbiological laboratory testing in the diagnosis of fungal infections in pulmonary and critical care practice. An official American Thoracic Society Clinical Practice Guideline. *Am J Respir Crit Care Med* 2019;200:535-50.

**Competing interests:** None declared.

This article has been peer reviewed.

**Affiliations:** Department of Laboratory Medicine and Pathobiology (Tat, Kus) and of Medicine (Nadarajah), Temerty Faculty of Medicine, University of Toronto; Public Health Ontario (Nadarajah, Kus), Toronto, Ont.; Oak Valley Health (Nadarajah), Markham Stouffville Hospital, Markham, Ont.

**Content licence:** This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is noncommercial (i.e., research or educational use), and no modifications or adaptations are made. See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>

**Correspondence to:** Julianne Kus, [julianne.kus@oahpp.ca](mailto:julianne.kus@oahpp.ca)

*CMAJ* invites submissions to “Five things to know about ...” Submit manuscripts online at <http://mc.manuscriptcentral.com/cmaj>.